Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:nicotinamide
go back to main search page
Accession:CHEBI:17154 term browser browse the term
Definition:A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Synonyms:related_synonym: 3-carbamoylpyridine;   3-pyridinecarboxamide;   Formula=C6H6N2O;   InChI=1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9);   InChIKey=DFPAKSUCGFBDDF-UHFFFAOYSA-N;   Niacinamide;   Nicotinamid;   Nicotinic acid amide;   Nicotinsaeureamid;   Nikotinamid;   Nikotinsaeureamid;   SMILES=NC(=O)c1cccnc1;   Vitamin PP;   beta-pyridinecarboxamide;   m-(aminocarbonyl)pyridine;   niacin;   niamide;   nicotinamida;   nicotinamidum;   nicotine acid amide;   nicotine amide;   nicotinic amide;   nicotylamide;   pyridine-3-carboxamide;   pyridine-3-carboxylic acid amide;   vitamin B3
 alt_id: CHEBI:14645;   CHEBI:25521;   CHEBI:44258;   CHEBI:7556
 xref: Beilstein:383619;   CAS:98-92-0;   DrugBank:DB02701;   Drug_Central:1906;   FooDB:FDB012485;   Gmelin:3336;   HMDB:HMDB0001406;   KEGG:C00153;   KEGG:D00036;   KNApSAcK:C00000209;   LINCS:LSM-5428
 xref_mesh: MESH:D009536
 xref: MetaCyc:NIACINAMIDE;   PDBeChem:NCA;   PMID:10884473;   PMID:11355130;   PMID:11814060;   PMID:12014919;   PMID:12487919;   PMID:12519385;   PMID:12709297;   PMID:12782109;   PMID:12890690;   PMID:14729974;   PMID:14757966;   PMID:14871431;   PMID:15497767;   PMID:15563975;   PMID:15780941;   PMID:15807725;   PMID:15834926;   PMID:15995937;   PMID:16029679;   PMID:16209160;   PMID:16596767;   PMID:16766489;   PMID:16871361;   PMID:17021258;   PMID:17129213;   PMID:18234191;   PMID:18316796;   PMID:18368629;   PMID:18373238;   PMID:18389009;   PMID:18514428;   PMID:18930755;   PMID:18987186;   PMID:19212411;   PMID:19539713;   PMID:19544437;   PMID:2026685;   PMID:21503886;   PMID:21891976;   PMID:21918528;   PMID:21926578;   PMID:22067079;   PMID:22160932;   PMID:22207684;   PMID:22232263;   PMID:22281243;   PMID:22359146;   PMID:22361740;   PMID:22407380;   PMID:22456321;   PMID:22536229;   PMID:22543086;   PMID:22626821;   PMID:22699421;   PMID:22709272;   PMID:22763693;   PMID:22770225;   PMID:23016598;   PMID:23028781;   PMID:23043891;   PMID:23047329;   PMID:24027187;   PMID:24077178;   PMID:24559077;   PMID:24635573;   PMID:25504347;   PMID:25561219;   PMID:31710686;   PMID:32249824;   PMID:33196157;   PMID:33471934;   PMID:8620561;   PMID:8767167;   PMID:9518388;   Patent:US2904552;   Patent:US2993051;   Reaxys:383619;   Wikipedia:Nicotinamide



show annotations for term's descendants           Sort by:
nicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP-binding cassette, sub-family A member 1 multiple interactions ISO nicotinamide inhibits the reaction [5/6 nephrectomy increases the expression of Abca1 protein in kidney] RGD PMID:19878707 RGD:2326081 NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895
JBrowse link
G Acaca acetyl-Coenzyme A carboxylase alpha multiple interactions
decreases phosphorylation
ISO Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of ACACA protein]
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]
Niacinamide results in decreased phosphorylation of ACACA protein
CTD PMID:18482975 PMID:19071085 PMID:21212096 NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477
JBrowse link
G Ace angiotensin I converting enzyme multiple interactions EXP 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA] CTD PMID:37120126 NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
JBrowse link
G Ace2 angiotensin converting enzyme 2 multiple interactions EXP 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA]; [Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA] CTD PMID:37120126 NCBI chr  X:162,922,338...162,971,414
Ensembl chr  X:162,922,328...162,971,416
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing increases secretion
multiple interactions
EXP
ISO
Niacinamide results in increased secretion of ADIPOQ protein
[Alloxan co-treated with Niacinamide] affects the expression of ADIPOQ protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein]
CTD PMID:17452443 PMID:21439372 PMID:26429928 NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
JBrowse link
G Ago2 argonaute RISC catalytic subunit 2 multiple interactions EXP Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 protein] CTD PMID:24792773 NCBI chr15:72,967,693...73,056,777
Ensembl chr15:72,967,693...73,056,784
JBrowse link
G Agtr1a angiotensin II receptor, type 1a multiple interactions ISO
EXP
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA]
CTD PMID:18420994 PMID:37120126 NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850
JBrowse link
G Akt1 thymoma viral proto-oncogene 1 multiple interactions ISO [Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein] CTD PMID:37566541 NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions EXP [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein] CTD PMID:25478867 NCBI chr10:90,825,173...90,918,688
Ensembl chr10:90,825,173...90,918,632
JBrowse link
G Bax BCL2-associated X protein multiple interactions
increases expression
ISO
EXP
Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of BAX protein]; Niacinamide inhibits the reaction [Thiotepa results in increased expression of BAX mRNA]; Niacinamide inhibits the reaction [Thiotepa results in increased expression of BAX protein]
[Berberine co-treated with Niacinamide] results in increased expression of BAX protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]
Niacinamide results in increased expression of BAX mRNA; Niacinamide results in increased expression of BAX protein
CTD PMID:16168987 PMID:16998810 PMID:22164206 PMID:25478867 PMID:26712469 NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
JBrowse link
G Bbc3 BCL2 binding component 3 multiple interactions
increases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA
Niacinamide results in increased expression of BBC3 mRNA
CTD PMID:26712469 NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130
JBrowse link
G Bcl2 B cell leukemia/lymphoma 2 multiple interactions EXP
ISO
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]
[Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]
CTD PMID:25472572 PMID:25478867 PMID:26712469 NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein]
Niacinamide results in increased expression of BCL2L11 mRNA
CTD PMID:25472572 PMID:26712469 NCBI chr 2:127,967,958...128,004,467
Ensembl chr 2:127,967,958...128,004,467
JBrowse link
G Bmi1 Bmi1 polycomb ring finger oncogene multiple interactions EXP Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 protein] CTD PMID:24792773 NCBI chr 2:18,681,953...18,691,440
Ensembl chr 2:18,681,829...18,691,440
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
ISO
EXP
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; Niacinamide inhibits the reaction [Thiotepa results in increased activity of CASP3 protein]
Niacinamide results in increased cleavage of CASP3 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; resveratrol inhibits the reaction [Niacinamide results in increased cleavage of CASP3 protein]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide promotes the reaction [Antimycin A results in increased cleavage of CASP3 protein]; Niacinamide promotes the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]
CTD PMID:16505238 PMID:22164206 PMID:24040102 PMID:24962570 PMID:25478867 More... NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
JBrowse link
G Casp9 caspase 9 multiple interactions ISO
EXP
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein]
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]
CTD PMID:16505238 PMID:25478867 PMID:26712469 NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
JBrowse link
G Cat catalase multiple interactions ISO
EXP
[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein]; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Pioglitazone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Saponins inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]
CTD PMID:20307516 PMID:21382363 PMID:21439372 PMID:21630391 PMID:22056647 More... NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression ISO Niacinamide results in decreased expression of CCL2 protein CTD PMID:14627904 NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
JBrowse link
G Ccl20 C-C motif chemokine ligand 20 increases expression ISO Niacinamide results in increased expression of CCL20 mRNA CTD PMID:22385246 NCBI chr 1:83,094,487...83,096,888
Ensembl chr 1:83,094,487...83,096,888
JBrowse link
G Cd36 CD36 molecule decreases expression ISO nicotinamide decreases expression of Cd36 protein in kidney RGD PMID:19878707 RGD:2326081 NCBI chr 5:17,986,680...18,093,828
Ensembl chr 5:17,986,688...18,093,799
JBrowse link
G Cd38 CD38 antigen multiple interactions EXP CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr 5:44,026,153...44,069,714
Ensembl chr 5:44,025,895...44,069,717
JBrowse link
G Cd40 CD40 antigen multiple interactions EXP Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA] CTD PMID:22717288 NCBI chr 2:164,897,535...164,913,574
Ensembl chr 2:164,897,547...164,914,868
JBrowse link
G Cdkn1a cyclin dependent kinase inhibitor 1A multiple interactions
increases expression
decreases expression
ISO
EXP
Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1A protein]
Niacinamide results in increased expression of CDKN1A protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]
Niacinamide results in decreased expression of CDKN1A protein
CTD PMID:12782109 PMID:22561310 PMID:25478867 NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
JBrowse link
G Cdkn1b cyclin dependent kinase inhibitor 1B increases expression
multiple interactions
ISO Niacinamide results in increased expression of CDKN1B protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]
CTD PMID:22561310 NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
JBrowse link
G Cdkn2a cyclin dependent kinase inhibitor 2A multiple interactions EXP Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter] CTD PMID:24792773 NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890
JBrowse link
G Chuk conserved helix-loop-helix ubiquitous kinase increases activity
multiple interactions
ISO Niacinamide results in increased activity of CHUK protein
resveratrol inhibits the reaction [Niacinamide results in increased activity of CHUK protein]
CTD PMID:24962570 NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
JBrowse link
G Col1a1 collagen, type I, alpha 1 decreases expression
multiple interactions
EXP
ISO
Niacinamide results in decreased expression of COL1A1 mRNA
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]
CTD PMID:16813520 PMID:25707573 NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
JBrowse link
G Col1a2 collagen, type I, alpha 2 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] CTD PMID:25707573 NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1a, liver decreases expression ISO Nicotinamide decreases expression of Cpt1a protein in kidney of 5/6 nephrectomized rats RGD PMID:19878707 RGD:2326081 NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733
JBrowse link
G Cxcl15 C-X-C motif chemokine ligand 15 increases expression
multiple interactions
ISO Niacinamide results in increased expression of CXCL8 mRNA
[Niacinamide co-treated with lipopolysaccharide, E. coli O26-B6] results in decreased expression of CXCL8 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of CXCL8 mRNA
CTD PMID:22385246 PMID:24894820 PMID:29594315 NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
JBrowse link
G Cyba cytochrome b-245, alpha polypeptide multiple interactions
increases expression
ISO Clofibrate inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]; GW 6471 inhibits the reaction [Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]]; Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA] CTD PMID:23422569 NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669
JBrowse link
G Cybb cytochrome b-245, beta polypeptide multiple interactions EXP 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NOX2 mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of NOX2 mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NOX2 mRNA] CTD PMID:37120126 NCBI chr  X:9,301,493...9,354,005
Ensembl chr  X:9,301,491...9,354,010
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions ISO Niacinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] CTD PMID:32298659 NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA] CTD PMID:27919644 NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
JBrowse link
G Defb4 defensin beta 4 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA CTD PMID:24894820 NCBI chr 8:19,248,720...19,251,563
Ensembl chr 8:19,248,722...19,251,561
JBrowse link
G Dicer1 dicer 1, ribonuclease type III multiple interactions EXP Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 protein] CTD PMID:24792773 NCBI chr12:104,654,001...104,718,331
Ensembl chr12:104,654,001...104,718,211
JBrowse link
G Dlg1 discs large MAGUK scaffold protein 1 multiple interactions EXP [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; Niacinamide inhibits the reaction [geranylgeranylacetone results in increased expression of DLG1 mRNA] CTD PMID:21232033 NCBI chr16:31,482,261...31,692,174
Ensembl chr16:31,482,261...31,693,947
JBrowse link
G Dnmt1 DNA methyltransferase 1 multiple interactions EXP Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 protein] CTD PMID:24792773 NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 increases phosphorylation
multiple interactions
ISO Niacinamide results in increased phosphorylation of EIF4EBP1 protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; Niacinamide inhibits the reaction [resveratrol results in decreased phosphorylation of EIF4EBP1 protein]
CTD PMID:19928762 PMID:20169165 NCBI chr 8:27,750,355...27,765,684
Ensembl chr 8:27,750,357...27,766,702
JBrowse link
G Ercc6 excision repair cross-complementing rodent repair deficiency, complementation group 6 increases abundance
multiple interactions
ISO ERCC6 gene mutant form results in increased abundance of Niacinamide
ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in decreased abundance of Niacinamide]
CTD PMID:25440059 NCBI chr14:32,235,248...32,302,947
Ensembl chr14:32,235,478...32,302,947
JBrowse link
G F3 coagulation factor III decreases expression ISO Niacinamide results in decreased expression of F3 protein CTD PMID:14627904 NCBI chr 3:121,517,186...121,528,701
Ensembl chr 3:121,517,186...121,528,697
JBrowse link
G Fabp1 fatty acid binding protein 1, liver multiple interactions ISO nicotinamide inhibits the reaction [5/6 nephrectomy decreases the expression of Fabp1 protein in kidney] RGD PMID:19878707 RGD:2326081 NCBI chr 6:71,176,863...71,182,018
Ensembl chr 6:71,176,811...71,182,007
JBrowse link
G Fasl Fas ligand multiple interactions EXP CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
JBrowse link
G Fos FBJ osteosarcoma oncogene multiple interactions ISO Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of FOS protein] CTD PMID:16168987 NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
JBrowse link
G Foxo1 forkhead box O1 multiple interactions EXP
ISO
Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC1 mRNA]; Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA]
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Niacinamide results in increased expression of and results in increased acetylation of FOXO1 protein
Niacinamide inhibits the reaction [Dexamethasone results in decreased acetylation of FOXO1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]
CTD PMID:16917544 PMID:20181797 PMID:26712469 NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
JBrowse link
G Foxo3 forkhead box O3 multiple interactions ISO [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of and results in increased expression of FOXO3 protein]]; Niacinamide inhibits the reaction [resveratrol results in increased expression of FOXO3 protein]; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of FOXO3 protein]; Niacinamide results in increased expression of and results in increased acetylation of FOXO3 protein CTD PMID:23022493 PMID:25472572 PMID:26712469 NCBI chr10:42,057,841...42,152,691
Ensembl chr10:42,057,837...42,152,751
JBrowse link
G Fth1 ferritin heavy polypeptide 1 increases expression ISO Niacinamide results in increased expression of FTH1 mRNA; Niacinamide results in increased expression of FTH1 protein CTD PMID:23738040 NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 multiple interactions EXP Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC1 mRNA] CTD PMID:16917544 NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729
JBrowse link
G G6pdx glucose-6-phosphate dehydrogenase X-linked multiple interactions ISO [Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein] CTD PMID:19059388 NCBI chr  X:73,453,089...73,472,486
Ensembl chr  X:73,453,089...73,472,800
JBrowse link
G Gcg glucagon multiple interactions ISO [Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA; Sitagliptin Phosphate inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA] CTD PMID:23466488 NCBI chr 2:62,304,874...62,313,997
Ensembl chr 2:62,304,874...62,313,994
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein] CTD PMID:21439372 NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions
increases expression
ISO Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
Niacinamide results in increased expression of GLB1 protein
CTD PMID:22561310 NCBI chr 9:114,230,146...114,303,447
Ensembl chr 9:114,230,144...114,303,966
JBrowse link
G Glo1 glyoxalase 1 multiple interactions ISO [Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein] CTD PMID:21439372 NCBI chr17:30,811,835...30,831,633
Ensembl chr17:30,803,910...30,845,845
JBrowse link
G Gpt glutamic pyruvic transaminase, soluble multiple interactions ISO [Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of GPT protein] CTD PMID:32894639 NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
JBrowse link
G Gsr glutathione reductase multiple interactions ISO [Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in decreased expression of GSR protein]; [Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein] CTD PMID:20307516 PMID:21439372 PMID:32894639 NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
JBrowse link
G Gstm5 glutathione S-transferase, mu 5 multiple interactions ISO [Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA] CTD PMID:21439372 NCBI chr 3:107,803,240...107,806,002
Ensembl chr 3:107,803,137...107,806,002
JBrowse link
G Gstp1 glutathione S-transferase, pi 1 multiple interactions ISO [Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of GSTP1 protein] CTD PMID:32894639 NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985
JBrowse link
G Gys2 glycogen synthase 2 multiple interactions ISO [Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein] CTD PMID:19059388 NCBI chr 6:142,368,339...142,418,856
Ensembl chr 6:142,368,339...142,418,835
JBrowse link
G Hba-a2 hemoglobin alpha, adult chain 2 multiple interactions ISO [Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein] CTD PMID:19647726 NCBI chr11:32,246,492...32,247,310
Ensembl chr11:32,246,489...32,247,298
JBrowse link
G Hdac1 histone deacetylase 1 multiple interactions EXP Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 protein] CTD PMID:24792773 NCBI chr 4:129,409,897...129,436,516
Ensembl chr 4:129,409,897...129,436,506
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-Coenzyme A reductase multiple interactions
decreases expression
ISO [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]
Nicotinamide decreases expression of Hmgcr protein in kidney of 5/6 nephrectomized rats
CTD
RGD
PMID:20696151 PMID:21212096 PMID:19878707 RGD:2326081 NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein] CTD PMID:21439372 NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]] CTD PMID:24145604 NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
JBrowse link
G Ifng interferon gamma multiple interactions ISO [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA CTD PMID:29594315 NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions EXP Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA] CTD PMID:16917544 NCBI chr11:7,147,787...7,152,546
Ensembl chr11:7,147,782...7,152,546
JBrowse link
G Il10 interleukin 10 multiple interactions EXP 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein]; [Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein] CTD PMID:37120126 NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
JBrowse link
G Il18 interleukin 18 multiple interactions ISO [Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL18 mRNA CTD PMID:28322830 NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression
increases expression
ISO [Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein; [Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL1B mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]
Niacinamide results in decreased expression of IL1B mRNA
Niacinamide results in increased expression of IL1B mRNA
CTD PMID:20307516 PMID:21439372 PMID:22385246 PMID:28322830 PMID:29594315 NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
JBrowse link
G Il2 interleukin 2 multiple interactions ISO [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA CTD PMID:29594315 NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
JBrowse link
G Il6 interleukin 6 decreases expression
multiple interactions
ISO Niacinamide results in decreased expression of IL6 protein
[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]
CTD PMID:12727023 PMID:20307516 PMID:21439372 NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
JBrowse link
G Ins1 insulin I multiple interactions ISO [Niacinamide co-treated with Streptozocin] results in decreased expression of INS1 protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein; [Streptozocin co-treated with Niacinamide] results in decreased secretion of INS1 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased expression of INS1 protein]; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS1 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased secretion of INS1 protein] CTD PMID:16366736 PMID:19647726 PMID:21382363 PMID:21630391 PMID:25999625 More... NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
JBrowse link
G Ins2 insulin II multiple interactions ISO Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS protein] CTD PMID:16505238 NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
JBrowse link
G Insr insulin receptor multiple interactions ISO [Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein] CTD PMID:37566541 NCBI chr 8:3,200,922...3,329,649
Ensembl chr 8:3,172,061...3,329,617
JBrowse link
G Irs2 insulin receptor substrate 2 multiple interactions ISO [Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein] CTD PMID:37566541 NCBI chr 8:11,034,681...11,058,929
Ensembl chr 8:11,034,681...11,058,458
JBrowse link
G Jun jun proto-oncogene multiple interactions ISO Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of JUN protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of JUN protein] CTD PMID:16168987 NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
JBrowse link
G Keap1 kelch-like ECH-associated protein 1 multiple interactions ISO
EXP
[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]
2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA]; [Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA]
CTD PMID:21439372 PMID:37120126 NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
JBrowse link
G Klf4 Kruppel-like transcription factor 4 (gut) multiple interactions ISO [Streptozocin co-treated with Niacinamide] promotes the reaction [Dronabinol results in increased expression of KLF4 mRNA] CTD PMID:31081965 NCBI chr 4:55,527,137...55,536,984
Ensembl chr 4:55,527,143...55,532,466
JBrowse link
G Lcat lecithin cholesterol acyltransferase multiple interactions ISO [Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein] CTD PMID:20696151 NCBI chr 8:106,666,183...106,670,034
Ensembl chr 8:106,666,183...106,670,014
JBrowse link
G Lhb luteinizing hormone beta multiple interactions ISO Niacinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] CTD PMID:32298659 NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321
JBrowse link
G Lpl lipoprotein lipase multiple interactions ISO [Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein] CTD PMID:20696151 NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100
JBrowse link
G Mafa MAF bZIP transcription factor A multiple interactions ISO Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]] CTD PMID:16505238 NCBI chr15:75,617,350...75,620,170
Ensembl chr15:75,617,339...75,620,077
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form] CTD PMID:24145604 NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of MAPK8 protein] CTD PMID:16168987 NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
JBrowse link
G Mdm2 transformed mouse 3T3 cell double minute 2 increases expression ISO Niacinamide results in increased expression of MDM2 mRNA CTD PMID:16998810 NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663
JBrowse link
G Mir200a microRNA 200a multiple interactions EXP 2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A]; [Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A] CTD PMID:37120126 NCBI chr 4:156,139,353...156,139,442
Ensembl chr 4:156,139,353...156,139,442
JBrowse link
G Mir203 microRNA 203 multiple interactions EXP Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the expression of MIR203 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of MIR203 promoter] CTD PMID:24792773 NCBI chr12:112,097,314...112,097,389
Ensembl chr12:112,097,314...112,097,389
JBrowse link
G Mlxipl MLX interacting protein-like multiple interactions ISO nicotinamide inhibits the reaction [5/6 nephrectomy increases the expression of Mlxipl protein in kidney] RGD PMID:19878707 RGD:2326081 NCBI chr 5:135,118,744...135,168,622
Ensembl chr 5:135,118,744...135,167,236
JBrowse link
G Mmp9 matrix metallopeptidase 9 increases expression
multiple interactions
ISO Niacinamide results in increased expression of MMP9 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of MMP9 protein]
CTD PMID:24145604 PMID:24962570 NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
JBrowse link
G Msra methionine sulfoxide reductase A multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in increased expression of MSRA protein] CTD PMID:23022493 NCBI chr14:64,360,070...64,693,352
Ensembl chr14:64,360,074...64,693,352
JBrowse link
G mt-Co1 cytochrome c oxidase I, mitochondrial increases expression ISO Niacinamide results in increased expression of COX1 mRNA; Niacinamide results in increased expression of COX1 protein CTD PMID:23738040 NCBI chr MT:5,328...6,872
Ensembl chr MT:5,328...6,872
JBrowse link
G Mtor mechanistic target of rapamycin kinase increases phosphorylation
multiple interactions
ISO Niacinamide results in increased phosphorylation of MTOR protein
Niacinamide inhibits the reaction [resveratrol results in decreased phosphorylation of MTOR protein]
CTD PMID:19928762 NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
JBrowse link
G Myc myelocytomatosis oncogene multiple interactions EXP Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein]; Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in increased expression of and results in increased localization of MYC protein] CTD PMID:22028816 PMID:24792773 NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
JBrowse link
G Nabp2 nucleic acid binding protein 2 decreases ubiquitination
increases acetylation
multiple interactions
ISO Niacinamide results in decreased ubiquitination of NABP2 protein
Niacinamide results in increased acetylation of NABP2 protein
Niacinamide promotes the reaction [trichostatin A results in decreased ubiquitination of NABP2 protein]; Niacinamide promotes the reaction [trichostatin A results in increased acetylation of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in decreased ubiquitination of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in increased acetylation of NABP2 protein]
CTD PMID:26170237 NCBI chr10:128,237,263...128,247,426
Ensembl chr10:128,237,264...128,247,361
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase decreases expression
multiple interactions
ISO Niacinamide results in decreased expression of NAMPT protein
Niacinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA]
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein
CTD PMID:26712469 PMID:32298659 NCBI chr12:32,870,334...32,903,368
Ensembl chr12:32,869,544...32,903,348
JBrowse link
G Ncor1 nuclear receptor co-repressor 1 decreases expression
multiple interactions
EXP Niacinamide results in decreased expression of NCOR1 protein
Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]
CTD PMID:22539994 NCBI chr11:62,207,132...62,348,200
Ensembl chr11:62,207,252...62,349,367
JBrowse link
G Ndufa1 NADH:ubiquinone oxidoreductase subunit A1 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA1 mRNA] CTD PMID:23891692 NCBI chr  X:36,451,241...36,454,891
Ensembl chr  X:36,451,241...36,454,816
JBrowse link
G Ndufa13 NADH:ubiquinone oxidoreductase subunit A13 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 mRNA]; Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 protein] CTD PMID:23891692 NCBI chr 8:70,346,813...70,355,208
Ensembl chr 8:70,346,830...70,355,208
JBrowse link
G Ndufa2 NADH:ubiquinone oxidoreductase subunit A2 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA2 mRNA] CTD PMID:23891692 NCBI chr18:36,875,385...36,877,640
Ensembl chr18:36,875,385...36,877,610
JBrowse link
G Nfe2l2 nuclear factor, erythroid derived 2, like 2 multiple interactions ISO
EXP
[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]
2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein]; [Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein]
CTD PMID:21439372 PMID:37120126 NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
JBrowse link
G Nfkb1 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 multiple interactions ISO [Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of NFKB1 mRNA] CTD PMID:32894639 NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
JBrowse link
G Nos2 nitric oxide synthase 2, inducible multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 mRNA]; Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 protein] CTD PMID:23735732 NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions
increases expression
ISO GW 6471 inhibits the reaction [resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA] CTD PMID:23422569 NCBI chr 7:86,893,638...87,047,918
Ensembl chr 7:86,895,304...87,047,918
JBrowse link
G Nqo1 NAD(P)H dehydrogenase, quinone 1 multiple interactions EXP 2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA] CTD PMID:37120126 NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 multiple interactions EXP [Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA CTD PMID:20505214 NCBI chr15:101,151,783...101,172,676
Ensembl chr15:101,152,150...101,172,676
JBrowse link
G Ogdh oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) multiple interactions ISO Niacinamide inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of OGDH protein] CTD PMID:18381761 NCBI chr11:6,241,597...6,309,094
Ensembl chr11:6,241,633...6,306,642
JBrowse link
G Parp1 poly (ADP-ribose) polymerase family, member 1 multiple interactions
increases expression
increases cleavage
decreases activity
ISO Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of PARP1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Thiotepa results in increased cleavage of PARP1 protein]
Niacinamide results in increased expression of PARP1 mRNA; Niacinamide results in increased expression of PARP1 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein; Niacinamide inhibits the reaction [sodium arsenite results in decreased expression of PARP1 protein]
Niacinamide results in increased cleavage of PARP1 protein
Niacinamide results in decreased activity of PARP1 protein
CTD PMID:16168987 PMID:19288225 PMID:22164206 PMID:26712469 PMID:29143419 More... NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
JBrowse link
G Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4 multiple interactions ISO Niacinamide inhibits the reaction [Dexamethasone results in increased expression of PDK4 protein] CTD PMID:20181797 NCBI chr 6:5,483,351...5,496,278
Ensembl chr 6:5,483,351...5,496,309
JBrowse link
G Pdp1 pyruvate dehydrogenase phosphatase catalytic subunit 1 multiple interactions ISO Niacinamide inhibits the reaction [Dexamethasone results in increased phosphorylation of PDP1 protein] CTD PMID:20181797 NCBI chr 4:11,958,183...11,966,450
Ensembl chr 4:11,958,184...11,966,452
JBrowse link
G Pitx2 paired-like homeodomain transcription factor 2 increases expression ISO Niacinamide results in increased expression of PITX2 mRNA; Niacinamide results in increased expression of PITX2 protein CTD PMID:29143419 NCBI chr 3:128,993,527...129,013,243
Ensembl chr 3:128,993,527...129,013,240
JBrowse link
G Pmp22 peripheral myelin protein 22 multiple interactions EXP Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of and results in decreased localization of PMP22 protein] CTD PMID:22028816 NCBI chr11:63,019,808...63,050,373
Ensembl chr11:63,019,808...63,050,373
JBrowse link
G Pparg peroxisome proliferator activated receptor gamma multiple interactions
increases expression
EXP
ISO
Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PPARG protein]
[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein]
CTD PMID:22539994 PMID:37566541 NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
JBrowse link
G Ppargc1a peroxisome proliferative activated receptor, gamma, coactivator 1 alpha increases acetylation
multiple interactions
ISO
EXP
Niacinamide results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]
CTD PMID:19071085 PMID:23422569 PMID:23891692 NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
JBrowse link
G Prkaa1 protein kinase, AMP-activated, alpha 1 catalytic subunit multiple interactions ISO Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA1 protein] CTD PMID:18482975 NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380
JBrowse link
G Prkaa2 protein kinase, AMP-activated, alpha 2 catalytic subunit multiple interactions ISO Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA2 protein] CTD PMID:18482975 NCBI chr 4:104,886,846...104,967,095
Ensembl chr 4:104,887,071...104,967,087
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO Niacinamide results in increased expression of PTGS2 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PTGS2 protein]
CTD PMID:24145604 PMID:24962570 NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
JBrowse link
G Pygl liver glycogen phosphorylase multiple interactions ISO [Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein] CTD PMID:19059388 NCBI chr12:70,237,589...70,274,457
Ensembl chr12:70,237,585...70,278,262
JBrowse link
G Rela v-rel reticuloendotheliosis viral oncogene homolog A (avian) multiple interactions ISO
EXP
[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]; Niacinamide inhibits the reaction [AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Metformin inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Salicylic Acid inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]
Niacinamide results in increased acetylation of and results in increased phosphorylation of RELA protein; resveratrol inhibits the reaction [Niacinamide results in increased phosphorylation of and results in increased acetylation of RELA protein]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein]; [Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein]; Niacinamide inhibits the reaction [Resveratrol results in decreased expression of RELA protein modified form]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]
CTD PMID:20307516 PMID:21439372 PMID:22717288 PMID:23406761 PMID:23735732 More... NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein CTD PMID:20169165 NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649
JBrowse link
G Runx2 runt related transcription factor 2 decreases expression
multiple interactions
increases expression
EXP
ISO
Niacinamide results in decreased expression of RUNX2 mRNA; Niacinamide results in decreased expression of RUNX2 protein
resveratrol inhibits the reaction [Niacinamide results in decreased expression of RUNX2 protein]
Niacinamide results in increased expression of RUNX2 mRNA
CTD PMID:16813520 PMID:22539994 NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684
JBrowse link
G Scaf1 SR-related CTD-associated factor 1 increases expression ISO nicotinamide increases expression of Scaf1 protein in kidney RGD PMID:19878707 RGD:2326081 NCBI chr 7:44,652,372...44,665,537
Ensembl chr 7:44,652,372...44,665,787
JBrowse link
G Scap SREBF chaperone increases expression ISO nicotinamide increases expression of Scap protein in kidney of 5/6 nephrectomized rat RGD PMID:19878707 RGD:2326081 NCBI chr 9:110,162,356...110,214,017
Ensembl chr 9:110,162,356...110,214,018
JBrowse link
G Scarb1 scavenger receptor class B, member 1 decreases expression ISO nicotinamide inhibits the reaction [5/6 nephrectomy increases the expression of Scarb1 protein in kidney] RGD PMID:19878707 RGD:2326081 NCBI chr 5:125,354,151...125,418,082
Ensembl chr 5:125,354,151...125,418,158
JBrowse link
G Shc1 src homology 2 domain-containing transforming protein C1 multiple interactions
increases expression
ISO Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of SHC1 protein]
Niacinamide results in increased expression of SHC1 mRNA; Niacinamide results in increased expression of SHC1 protein
CTD PMID:21778425 PMID:24557422 NCBI chr 3:89,325,858...89,337,336
Ensembl chr 3:89,325,750...89,337,334
JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression
decreases activity
EXP
ISO
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol; Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA]
Niacinamide results in decreased expression of SIRT1 protein
[Niacinamide co-treated with Resveratrol] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Glucose]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to AICA ribonucleotide; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Fructose; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Metformin; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Resveratrol; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Salicylic Acid; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA; [Resveratrol co-treated with Niacinamide] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of and results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]; Niacinamide inhibits the reaction [Resveratrol promotes the reaction [Pilocarpine results in increased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 mRNA]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]
Niacinamide results in decreased expression of SIRT1 mRNA; Niacinamide results in decreased expression of SIRT1 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of CXCL8 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased susceptibility to Hydrogen Peroxide; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]]; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]]; Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]
CTD PMID:16366736 PMID:17103016 PMID:18420994 PMID:18482975 PMID:18681908 More... NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
JBrowse link
G Sirt2 sirtuin 2 decreases activity
multiple interactions
ISO Niacinamide results in decreased activity of SIRT2 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein
CTD PMID:17341628 PMID:26712469 NCBI chr 7:28,466,192...28,488,086
Ensembl chr 7:28,466,160...28,488,086
JBrowse link
G Sirt3 sirtuin 3 multiple interactions ISO [Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein CTD PMID:26712469 NCBI chr 7:140,443,576...140,462,222
Ensembl chr 7:140,443,579...140,462,222
JBrowse link
G Slc2a4 solute carrier family 2 (facilitated glucose transporter), member 4 multiple interactions ISO [Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein]; Niacinamide inhibits the reaction [Letrozole results in decreased expression of SLC2A4 mRNA]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein] CTD PMID:32298659 PMID:37566541 NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects abundance EXP SLCO1A4 protein affects the abundance of Niacinamide CTD PMID:21561886 NCBI chr 6:141,751,164...141,802,011
Ensembl chr 6:141,751,166...141,801,925
JBrowse link
G Snap23 synaptosomal-associated protein 23 multiple interactions ISO [Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA] CTD PMID:25999625 NCBI chr 2:120,398,137...120,436,829
Ensembl chr 2:120,398,152...120,431,736
JBrowse link
G Sod1 superoxide dismutase 1, soluble multiple interactions ISO
EXP
[Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein; Dronabinol promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein]; [Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein]
CTD PMID:31081965 PMID:37120126 NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
JBrowse link
G Sod2 superoxide dismutase 2, mitochondrial multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in increased expression of SOD2 mRNA]
Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SOD2 protein]
CTD PMID:23891692 PMID:25472572 NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
JBrowse link
G Sox9 SRY (sex determining region Y)-box 9 decreases expression
multiple interactions
ISO Niacinamide results in decreased expression of SOX9 protein
4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]; resveratrol inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]
CTD PMID:24962570 NCBI chr11:112,673,036...112,678,583
Ensembl chr11:112,673,050...112,678,586
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions EXP Niacinamide inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein] CTD PMID:24238063 NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO Niacinamide inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]] CTD PMID:23319015 NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
JBrowse link
G Stx4a syntaxin 4A (placental) multiple interactions ISO [Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA] CTD PMID:25999625 NCBI chr 7:127,439,832...127,450,160
Ensembl chr 7:127,423,466...127,448,191
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein]; [Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein] CTD PMID:37120126 NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
JBrowse link
G Tgfb2 transforming growth factor, beta 2 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] CTD PMID:25707573 NCBI chr 1:186,354,984...186,441,504
Ensembl chr 1:186,354,989...186,438,186
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
ISO
EXP
[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]
Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]; Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA]
Niacinamide results in increased expression of TNF mRNA
CTD PMID:20307516 PMID:21439372 PMID:22385246 PMID:22717288 PMID:24145604 More... NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
JBrowse link
G Tnfrsf11b tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) decreases expression EXP Niacinamide results in decreased expression of TNFRSF11B mRNA CTD PMID:16813520 NCBI chr15:54,114,014...54,141,700
Ensembl chr15:54,114,015...54,141,880
JBrowse link
G Tnfsf11 tumor necrosis factor (ligand) superfamily, member 11 decreases expression EXP Niacinamide results in decreased expression of TNFSF11 mRNA CTD PMID:16813520 NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
JBrowse link
G Trp53 transformation related protein 53 multiple interactions
decreases expression
ISO
EXP
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of TP53 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]; Niacinamide results in increased phosphorylation of and results in increased acetylation of TP53 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]
Niacinamide results in decreased expression of TP53 protein
CTD PMID:12782109 PMID:18482975 PMID:18681908 PMID:25478867 PMID:26712469 NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
JBrowse link
G Tyr tyrosinase increases expression ISO Niacinamide results in increased expression of TYR mRNA; Niacinamide results in increased expression of TYR protein CTD PMID:23738040 NCBI chr 7:87,073,979...87,142,637
Ensembl chr 7:87,073,979...87,142,720
JBrowse link
G Ucp2 uncoupling protein 2 (mitochondrial, proton carrier) multiple interactions EXP Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA] CTD PMID:16366736 NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227
JBrowse link
G Vamp2 vesicle-associated membrane protein 2 multiple interactions ISO [Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA] CTD PMID:25999625 NCBI chr11:68,979,354...68,983,207
Ensembl chr11:68,979,316...68,983,210
JBrowse link
1-methylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] CTD PMID:32298659 NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611
JBrowse link
G Dek DEK proto-oncogene decreases chemical synthesis ISO DEK protein results in decreased chemical synthesis of N(1)-methylnicotinamide CTD PMID:28558019 NCBI chr13:47,238,243...47,261,134
Ensembl chr13:47,238,251...47,259,677
JBrowse link
G Lepr leptin receptor affects abundance EXP LEPR affects the abundance of N(1)-methylnicotinamide CTD PMID:20567778 NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549
JBrowse link
G Lhb luteinizing hormone beta multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] CTD PMID:32298659 NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA] CTD PMID:32298659 NCBI chr12:32,870,334...32,903,368
Ensembl chr12:32,869,544...32,903,348
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression ISO N(1)-methylnicotinamide results in increased expression of PTGS2 mRNA CTD PMID:18385449 NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
JBrowse link
G Retn resistin multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of RETN mRNA] CTD PMID:32298659 NCBI chr 8:3,705,770...3,709,818
Ensembl chr 8:3,705,770...3,710,110
JBrowse link
G Slc22a1 solute carrier family 22 (organic cation transporter), member 1 increases import ISO SLC22A1 results in increased import of N(1)-methylnicotinamide CTD PMID:9260930 NCBI chr17:12,867,761...12,894,725
Ensembl chr17:12,867,756...12,894,716
JBrowse link
G Slc22a16 solute carrier family 22 (organic cation transporter), member 16 multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [SLC22A16 protein results in increased uptake of Tetraethylammonium] CTD PMID:15963465 NCBI chr10:40,446,317...40,480,128
Ensembl chr10:40,446,332...40,480,128
JBrowse link
G Slc22a2 solute carrier family 22 (organic cation transporter), member 2 increases import ISO SLC22A2 results in increased import of N(1)-methylnicotinamide CTD PMID:9260930 NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375
JBrowse link
G Slc22a3 solute carrier family 22 (organic cation transporter), member 3 multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] CTD PMID:10966924 NCBI chr17:12,638,859...12,726,591
Ensembl chr17:12,637,847...12,726,591
JBrowse link
N-methylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Idh2 isocitrate dehydrogenase 2 (NADP+), mitochondrial increases abundance
multiple interactions
EXP IDH2 protein mutant form results in increased abundance of N-methylnicotinamide
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of N-methylnicotinamide]
CTD PMID:27469509 NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects abundance EXP SLCO1A4 protein affects the abundance of N-methylnicotinamide CTD PMID:21561886 NCBI chr 6:141,751,164...141,802,011
Ensembl chr 6:141,751,166...141,801,925
JBrowse link
N-ribosylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ercc6 excision repair cross-complementing rodent repair deficiency, complementation group 6 multiple interactions EXP nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate]; nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD] CTD PMID:25440059 NCBI chr14:32,235,248...32,302,947
Ensembl chr14:32,235,478...32,302,947
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide quinone reductase 2 multiple interactions
increases oxidation
ISO [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of 2,6-Dichloroindophenol; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q1; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]
NQO2 protein results in increased oxidation of nicotinamide-beta-riboside; NQO2 protein results in increased oxidation of nicotinamide-beta-riboside metabolite
CTD PMID:20399199 PMID:29281794 NCBI chr13:34,148,642...34,172,448
Ensembl chr13:34,148,670...34,172,426
JBrowse link
nicorandil term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc9 ATP-binding cassette, sub-family C member 9 increases activity EXP Nicorandil results in increased activity of ABCC9 protein CTD PMID:22622455 NCBI chr 6:142,533,592...142,648,472
Ensembl chr 6:142,533,588...142,648,041
JBrowse link
G Agt angiotensinogen multiple interactions EXP Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein] CTD PMID:22622455 NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
JBrowse link
G Alb albumin multiple interactions EXP Nicorandil inhibits the reaction [Folic Acid results in decreased expression of ALB protein] CTD PMID:33404076 NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
JBrowse link
G Bax BCL2-associated X protein multiple interactions ISO
EXP
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of BAX protein]
Nicorandil inhibits the reaction [Folic Acid results in increased expression of BAX protein]
CTD PMID:31376360 PMID:33404076 NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
JBrowse link
G Bcl2 B cell leukemia/lymphoma 2 multiple interactions ISO Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] CTD PMID:31376360 NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
JBrowse link
G Casp3 caspase 3 multiple interactions EXP Nicorandil inhibits the reaction [Folic Acid results in increased expression of CASP3 protein] CTD PMID:33404076 NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
JBrowse link
G Cat catalase multiple interactions ISO Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of CAT protein] CTD PMID:31376360 NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
JBrowse link
G Ctsd cathepsin D multiple interactions ISO [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of CTSD protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] CTD PMID:11829124 PMID:14499179 NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775
JBrowse link
G Gal galanin and GMAP prepropeptide multiple interactions ISO [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GAL protein] CTD PMID:11829124 PMID:14499179 NCBI chr19:3,459,915...3,464,544
Ensembl chr19:3,459,915...3,464,544
JBrowse link
G Gusb glucuronidase, beta multiple interactions ISO [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] CTD PMID:11829124 PMID:14499179 NCBI chr 5:130,011,278...130,031,890
Ensembl chr 5:130,017,852...130,031,890
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions ISO Nicorandil inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] CTD PMID:31376360 NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405
JBrowse link
G Hmox1 heme oxygenase 1 decreases expression ISO Nicorandil results in decreased expression of HMOX1 protein CTD PMID:22622455 NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO Nicorandil inhibits the reaction [Doxorubicin results in increased expression of IL1B protein] CTD PMID:31376360 NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
JBrowse link
G Il6 interleukin 6 multiple interactions EXP Nicorandil inhibits the reaction [Folic Acid results in increased expression of IL6 protein] CTD PMID:33404076 NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO Nicorandil inhibits the reaction [Doxorubicin results in increased expression of MPO protein] CTD PMID:31376360 NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
JBrowse link
G Nfe2l2 nuclear factor, erythroid derived 2, like 2 multiple interactions ISO Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein] CTD PMID:31376360 NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
JBrowse link
G Nfkb1 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 multiple interactions ISO Nicorandil inhibits the reaction [Doxorubicin results in increased expression of NFKB1 protein] CTD PMID:31376360 NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
JBrowse link
G Nos2 nitric oxide synthase 2, inducible multiple interactions EXP Nicorandil inhibits the reaction [Folic Acid results in increased expression of NOS2 protein] CTD PMID:33404076 NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
JBrowse link
G Nos3 nitric oxide synthase 3, endothelial cell multiple interactions EXP Nicorandil inhibits the reaction [Folic Acid results in decreased expression of NOS3 protein] CTD PMID:33404076 NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
JBrowse link
G Sod2 superoxide dismutase 2, mitochondrial increases expression ISO Nicorandil results in increased expression of SOD2 protein CTD PMID:22622455 NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TLR4 protein] CTD PMID:31376360 NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TNF protein]
Nicorandil inhibits the reaction [Folic Acid results in increased expression of TNF protein]
CTD PMID:31376360 PMID:33404076 NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
JBrowse link
G Xdh xanthine dehydrogenase multiple interactions
decreases expression
EXP
ISO
Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein]
Nicorandil results in decreased expression of XDH protein
CTD PMID:22622455 NCBI chr17:74,190,890...74,257,191
Ensembl chr17:74,190,890...74,257,191
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 22205
    role 22190
      chemical role 21439
        antioxidant 16400
          nicotinamide 164
            1-[(2-chlorophenyl)methyl]-2-oxo-6-(trifluoromethyl)-3-pyridinecarboxamide 0
            1-[[oxo(3-pyridinyl)methyl]amino]-3-(4-propan-2-ylphenyl)thiourea 0
            1-methylnicotinamide + 11
            2-(2,4-dimethylanilino)-N-(thiophen-2-ylmethyl)-3-pyridinecarboxamide 0
            2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide 0
            2-(4-chloro-2-methylanilino)-3-pyridinecarboxamide 0
            2-(methylthio)nicotinamide 0
            2-methylnicotinamide 0
            2-oxo-N-(2-thiazolyl)-1H-pyridine-3-carboxamide 0
            5-bromo-N-(4-methyl-2-thiazolyl)-3-pyridinecarboxamide 0
            5-bromo-N-[(2-pyridinylamino)-sulfanylidenemethyl]-3-pyridinecarboxamide 0
            5-bromo-N-[(5-nitro-2-thiophenyl)methylideneamino]-3-pyridinecarboxamide 0
            5-bromo-N-[[(3-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-3-pyridinecarboxamide 0
            5-bromo-N-[[(4-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-3-pyridinecarboxamide 0
            5-hydroxy-N-[2-[[(5-hydroxy-3-pyridinyl)-oxomethyl]amino]propyl]-3-pyridinecarboxamide 0
            6-Methylnicotinamide 0
            6-methoxy-4-(trifluoromethyl)nicotinamide 0
            6-methyl-N-(2-pyridinylmethylideneamino)-3-pyridinecarboxamide 0
            6-methyl-N-[(2-methyl-3-phenylprop-2-enylidene)amino]-3-pyridinecarboxamide 0
            Himeic acid G 0
            Myxochelin N 0
            Myxochelin O 0
            N'3-(3,4,5-trimethoxybenzylidene)pyridine-3-carbohydrazide 0
            N,N-Dihexylnicotinamide 0
            N-(1-adamantyl)-5-hydroxy-3-pyridinecarboxamide 0
            N-(2-fluorophenyl)-2-methyl-6-(trifluoromethyl)nicotinamide 0
            N-[(2-methyl-3-phenylprop-2-enylidene)amino]-3-pyridinecarboxamide 0
            N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2R,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2R,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2R,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2S,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
            N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2S,3R,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
            N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2S,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
            N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(2S,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
            N-[(3,3-dimethyl-5-oxocyclohexylidene)amino]-3-pyridinecarboxamide 0
            N-[1,1,1,3,3,3-hexafluoro-2-(2-pyridinylmethylamino)propan-2-yl]-3-pyridinecarboxamide 0
            N-[2-[2-[2-[[oxo(3-pyridinyl)methyl]amino]ethoxy]ethoxy]ethyl]-3-pyridinecarboxamide 0
            N-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]-3-pyridinecarboxamide 0
            N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-3-pyridinecarboxamide 0
            N-[6-(1-oxopentylamino)-3-pyridinyl]-3-pyridinecarboxamide 0
            N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4R,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4R,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4R,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4R,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4S,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4S,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4S,5R)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4S,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[(4S,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
            N-[[3-methoxy-4-[2-(4-methylanilino)-2-oxoethoxy]phenyl]methylideneamino]-3-pyridinecarboxamide 0
            N-[[5-(4-nitrophenyl)-2-furanyl]methylideneamino]-3-pyridinecarboxamide 0
            N-\{5-[4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl\}nicotinamide 0
            N-glycosylnicotinamide + 2
            N-methyl-N-[5-(3-pyridinyl)-1,3,4-thiadiazol-2-yl]-3-pyridinecarboxamide 0
            N-methylnicotinamide 2
            Nicoxamat 0
            Penipyridone A 0
            Penipyridone C 0
            Penipyridone D 0
            Penipyridone F 0
            Pestalamide C 0
            Pestalamide D 0
            Poronitin B 0
            acetic acid 2-[[oxo(3-pyridinyl)methyl]amino]ethyl ester 0
            flonicamid 0
            hydroxymethylnicotinamide 0
            nicorandil 23
            nikethamide 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 22205
    subatomic particle 22197
      composite particle 22197
        hadron 22197
          baryon 22197
            nucleon 22169
              atomic nucleus 22197
                atom 22197
                  main group element atom 22131
                    p-block element atom 22131
                      carbon group element atom 21928
                        carbon atom 21854
                          organic molecular entity 21854
                            heteroorganic entity 21512
                              organochalcogen compound 21001
                                organooxygen compound 20845
                                  carbon oxoacid 19638
                                    carboxylic acid 19631
                                      carboacyl group 18297
                                        univalent carboacyl group 18297
                                          carbamoyl group 18111
                                            carboxamide 18111
                                              pyridinecarboxamide 339
                                                nicotinamide 164
                                                  1-[(2-chlorophenyl)methyl]-2-oxo-6-(trifluoromethyl)-3-pyridinecarboxamide 0
                                                  1-[[oxo(3-pyridinyl)methyl]amino]-3-(4-propan-2-ylphenyl)thiourea 0
                                                  1-methylnicotinamide + 11
                                                  2-(2,4-dimethylanilino)-N-(thiophen-2-ylmethyl)-3-pyridinecarboxamide 0
                                                  2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide 0
                                                  2-(4-chloro-2-methylanilino)-3-pyridinecarboxamide 0
                                                  2-(methylthio)nicotinamide 0
                                                  2-methylnicotinamide 0
                                                  2-oxo-N-(2-thiazolyl)-1H-pyridine-3-carboxamide 0
                                                  5-bromo-N-(4-methyl-2-thiazolyl)-3-pyridinecarboxamide 0
                                                  5-bromo-N-[(2-pyridinylamino)-sulfanylidenemethyl]-3-pyridinecarboxamide 0
                                                  5-bromo-N-[(5-nitro-2-thiophenyl)methylideneamino]-3-pyridinecarboxamide 0
                                                  5-bromo-N-[[(3-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-3-pyridinecarboxamide 0
                                                  5-bromo-N-[[(4-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-3-pyridinecarboxamide 0
                                                  5-hydroxy-N-[2-[[(5-hydroxy-3-pyridinyl)-oxomethyl]amino]propyl]-3-pyridinecarboxamide 0
                                                  6-Methylnicotinamide 0
                                                  6-methoxy-4-(trifluoromethyl)nicotinamide 0
                                                  6-methyl-N-(2-pyridinylmethylideneamino)-3-pyridinecarboxamide 0
                                                  6-methyl-N-[(2-methyl-3-phenylprop-2-enylidene)amino]-3-pyridinecarboxamide 0
                                                  Himeic acid G 0
                                                  Myxochelin N 0
                                                  Myxochelin O 0
                                                  N'3-(3,4,5-trimethoxybenzylidene)pyridine-3-carbohydrazide 0
                                                  N,N-Dihexylnicotinamide 0
                                                  N-(1-adamantyl)-5-hydroxy-3-pyridinecarboxamide 0
                                                  N-(2-fluorophenyl)-2-methyl-6-(trifluoromethyl)nicotinamide 0
                                                  N-[(2-methyl-3-phenylprop-2-enylidene)amino]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
                                                  N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
                                                  N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
                                                  N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(3,3-dimethyl-5-oxocyclohexylidene)amino]-3-pyridinecarboxamide 0
                                                  N-[1,1,1,3,3,3-hexafluoro-2-(2-pyridinylmethylamino)propan-2-yl]-3-pyridinecarboxamide 0
                                                  N-[2-[2-[2-[[oxo(3-pyridinyl)methyl]amino]ethoxy]ethoxy]ethyl]-3-pyridinecarboxamide 0
                                                  N-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]-3-pyridinecarboxamide 0
                                                  N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-3-pyridinecarboxamide 0
                                                  N-[6-(1-oxopentylamino)-3-pyridinyl]-3-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[3-methoxy-4-[2-(4-methylanilino)-2-oxoethoxy]phenyl]methylideneamino]-3-pyridinecarboxamide 0
                                                  N-[[5-(4-nitrophenyl)-2-furanyl]methylideneamino]-3-pyridinecarboxamide 0
                                                  N-\{5-[4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl\}nicotinamide 0
                                                  N-glycosylnicotinamide + 2
                                                  N-methyl-N-[5-(3-pyridinyl)-1,3,4-thiadiazol-2-yl]-3-pyridinecarboxamide 0
                                                  N-methylnicotinamide 2
                                                  Nicoxamat 0
                                                  Penipyridone A 0
                                                  Penipyridone C 0
                                                  Penipyridone D 0
                                                  Penipyridone F 0
                                                  Pestalamide C 0
                                                  Pestalamide D 0
                                                  Poronitin B 0
                                                  acetic acid 2-[[oxo(3-pyridinyl)methyl]amino]ethyl ester 0
                                                  flonicamid 0
                                                  hydroxymethylnicotinamide 0
                                                  nicorandil 23
                                                  nikethamide 0
paths to the root